Apellis Pharmaceuticals Inc [APLS] stock prices are down -0.62% to $33.93 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The APLS shares have gain 22.27% over the last week, with a monthly amount glided 22.45%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Apellis Pharmaceuticals Inc [NASDAQ: APLS] stock has seen the most recent analyst activity on November 21, 2024, when Morgan Stanley initiated its Equal-Weight rating and assigned the stock a price target of $31. Previously, RBC Capital Mkts started tracking the stock with Sector Perform rating on October 25, 2024, and set its price target to $25. On October 16, 2024, William Blair initiated with a Outperform rating. Scotiabank started tracking the stock assigning a Sector Outperform rating. Piper Sandler initiated its recommendation with a Neutral and recommended $46 as its price target on May 31, 2024. Jefferies upgraded its rating to Buy for this stock on February 05, 2024, and upped its price target to $80. In a note dated December 14, 2023, Wells Fargo downgraded an Equal Weight rating on this stock.
The stock price of Apellis Pharmaceuticals Inc [APLS] has been fluctuating between $24.34 and $73.80 over the past year. Currently, Wall Street analysts expect the stock to reach $74.5 within the next 12 months. Apellis Pharmaceuticals Inc [NASDAQ: APLS] shares were valued at $33.93 at the most recent close of the market. An investor can expect a potential return of 119.57% based on the average APLS price forecast.
Analyzing the APLS fundamentals
The Apellis Pharmaceuticals Inc [NASDAQ:APLS] reported sales of 715.22M for trailing twelve months, representing a surge of 78.29%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.31%, Pretax Profit Margin comes in at -0.35%, and Net Profit Margin reading is -0.35%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -1.04 and Total Capital is -0.31. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.94.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 33.58 points at the first support level, and at 33.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 34.49, and for the 2nd resistance point, it is at 35.04.
Ratios To Look Out For
It’s worth pointing out that Apellis Pharmaceuticals Inc [NASDAQ:APLS]’s Current Ratio is 4.36. Further, the Quick Ratio stands at 3.73, while the Cash Ratio is 2.07. Considering the valuation of this stock, the price to sales ratio is 5.86, the price to book ratio is 17.47.
Transactions by insiders
Recent insider trading involved Dunlop A. Sinclair, Director, that happened on Sep 16 ’24 when 37000.0 shares were sold. VP/Chief Accounting Officer, Chopas James George completed a deal on Sep 16 ’24 to sell 192.0 shares. Meanwhile, Officer Chopas James George bought 192.0 shares on Sep 16 ’24.
